Also from this source


You just read:

U.S. FDA Approves Mylan and Biocon's Ogivri™, the First Biosimilar for Trastuzumab, for the Treatment of HER2-Positive Breast and Gastric Cancers

News provided by

Mylan N.V.

Dec 01, 2017, 10:31 EST